HALAVEN 0.44 mg/ml, solution for injection bottle, 2 ml
Active ingredients: Eribulin mesylate, Eribulin
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 2 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- HALAVEN 0,44 mg/ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon en verre de 2 mL
- Marketing authorisation holder
- EISAI (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 22 Mar 2012
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63816522CIP74183523CIP133400941835230Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉRIBULINEsolution | 0,88 mg · un flacon | FT |
| MÉSILATE D'ÉRIBULINEsolution | 1 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.